With a lens towards identifying key value, access, and pricing dynamics, our Cell and Gene Therapy Center of Excellence team can determine the influence these innovative treatments will have when entering the market.
Showing 5 of 13 posts
October 19, 2021 | Blogs
Explore themes from biotech and investors in the cell and gene therapy space, as well as future-facing cell and gene therapy trends, new developments in the space, as well as what’s next.
October 6, 2021 | Blogs
Some cell and gene therapies without a curative promise have shown encouraging results for patients with chronic disorders, however manufacturers need to carefully design a value strategy for their non-curative assets to ensure maximum access and uptake in their target markets.
November 3, 2020 | Blogs
New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.
September 22, 2020 | Blogs
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.
March 26, 2020 | Podcasts
In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.